The Sopharma Tribestan at Netrition.com. PDFs

The main objectives were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in contrast with placebo, for the treatment of men with erectile dysfunction (ED) and with or without hypoactive libido disorder (HSDD), in addition to to keep an eye on the safety profile of the drug.

Stage IV, prospective, randomized, double-blind, placebo-controlled scientific trial in parallel groups. This research study consisted of 180 males aged in between 18 and 65 years with moderate or moderate ED and with or without HSDD: 90 were randomized to TT and 90 to placebo. tribestan 250mg with ED and high blood pressure, diabetes mellitus, and metabolic syndrome were consisted of in the study.

Each Tribestan film-coated tablet consists of the active compound Tribulus terrestris, herba extractum siccum (35-45:1) 250mg which is standardized to furostanol saponins (not less than 112. 5mg). Each client received orally 32 film-coated tablets daily after meals, during the 12-week treatment duration. At the end of each month, individuals' sexual function, consisting of ED, was examined by International Index of Erectile Function (IIEF) Questionnaire and International Efficacy Concern (GEQ).

The main outcome procedure was the modification in IIEF score after 12 weeks of treatment. Complete randomization (random sorting utilizing maximum allowable% deviation) with an equivalent number of clients in each sequence was used. This randomization algorithm has the constraint that unequal treatment allotment is not allowed; that is, all groups should have the same target sample size.

All outcome assessors were also blinded to group allowance. 86 patients in each group finished the study. The IIEF rating enhanced considerably in the TT group compared to the placebo group (